english.prescrire.org > Spotlight > 100 most recent > Rating therapeutic advance: third comparison of Prescrire's drug ratings with those of the French HAS

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Rating therapeutic advance: third comparison of Prescrire's drug ratings with those of the French HAS

 Outlook  A comparative analysis of drug ratings assigned by Prescrire and France's National Authority for Health (HAS) reveals that the main differences between them concern the weight assigned to presumed innovation and to advances in ease of use.
Full article available for download (FREE)

 ©Prescrire 1 April 2026

Source: "Rating therapeutic advance: third comparison of Prescrire's drug ratings with those of the French HAS" Prescrire Int 2026; 35 (280): 108-109. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Prescrire's drug
ratings in 2025:
a brief review"
Prescrire Int 2026;
35 (280): 101-103.
FREE
 
"Towards better
patient care:
drugs to avoid in 2026"
Prescrire Int 2026;
35 (278): 54-55
(full version: 12 pages).
FREE